Top Markets
#1 Akedo Akedo +61.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.50%
#4 Cross Cross +46.58%
#5 Black Phoenix Black Phoenix +34.22%
#6 Velvet Velvet +31.90%
#7 OVERTAKE OVERTAKE +27.47%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.31%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +14.54%
#10 Movement Movement +13.62%
Coin of the day
Akedo Akedo
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Athenex, Inc. Athenex, Inc.

Athenex, Inc.

ATNX
Classement en actions #38801
Athenex, Inc. is a biopharmaceutical company primarily dedicated to the... Athenex, Inc. is a biopharmaceutical company primarily dedicated to the discovery, advancement, and commercialization of therapeutic agents for oncological conditions. Its operations are structured across three distinct platforms: an Oncology Innovation Platform, a Global Supply Chain Platform, and a Commercial Platform. Among its leading product candidates is the Orascovery series, featuring oral paclitaxel combined with encequidar – an innovative oral formulation. This product is currently undergoing a Phase III clinical trial for metastatic breast cancer, alongside earlier-stage studies for cutaneous angiosarcoma, advanced gastric cancer, and various other advanced solid malignancies. Additionally, Athenex offers Src Kinase inhibitors, exemplified by Tirbanibulin ointments, which are being developed for the treatment of actinic keratosis, certain skin cancers, and psoriasis. The company's pipeline further includes several advanced cell therapy programs. KUR-501, an autologous product, is in a Phase I clinical trial addressing relapsed-refractory (R/R) high-risk neuroblastoma in pediatric patients. KUR-502, an allogeneic product, is also in a Phase I clinical trial, targeting R/R CD19 positive malignancies in adults, such as B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. For advanced hepatocellular carcinomas, Athenex is progressing KUR-503, an allogeneic product in preclinical development. Moreover, TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy, is undergoing a Phase 1 clinical trial for solid tumors. Beyond these, Athenex is developing novel dual absorption enhancers designed to obstruct the P-gp transporter and cytochrome p450 3A enzymes within the gastrointestinal tract. It also possesses a robust portfolio of T cell receptors engineered to identify hotspot mutations in genes like p53, KRAS, and EGFR, applicable across multiple tumor types. Tracing its origins, the company was established in 2003 and was initially known as Kinex Pharmaceuticals LLC before officially adopting the name Athenex, Inc. in August 2015. Its corporate headquarters are situated in Buffalo, New York.
Prix de l'action
$0.2031
Dernière synchronisation: 2023-05-24
Capitalisation boursière
$797.69K
Changement (1 jour)
-23.39%
Changement (1 an)
0.00%
Pays
US
Échange Athenex, Inc. (ATNX)

Catégorie

Healthcare
Historique du prix de l'action pour Athenex, Inc. (ATNX)
Prix de clôture le plus élevé : $0.87 le 2023-05-01

Prix de clôture le plus bas : $300.51 le 2017-06-01
Historique du prix de l'action de Athenex, Inc. de 2017 à 2026
Performance annuelle du prix de l'action
Année Performance
2023 -73.50%
2022 -89.32%
2021 -87.17%
2020 -22.10%
2019 25.05%
2018 -24.65%
2017 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 $171.67 -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 $161.67 25.08%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 $36.61 23.93%
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 $225.00 38.71%
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $21.30 13.79%
IN